Arbutus Biopharma (ABUS) Competitors

Arbutus Biopharma (NASDAQ:ABUS) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment.

Does the media prefer ABUS or IMVT?

In the previous week, Immunovant had 7 more articles in the media than Arbutus Biopharma. MarketBeat recorded 11 mentions for Immunovant and 4 mentions for Arbutus Biopharma. Immunovant's average media sentiment score of 1.57 beat Arbutus Biopharma's score of 0.20 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more volatility and risk, ABUS or IMVT?

Arbutus Biopharma has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.

Do analysts rate ABUS or IMVT?

Arbutus Biopharma currently has a consensus price target of $5.50, indicating a potential upside of 71.34%. Immunovant has a consensus price target of $38.33, indicating a potential upside of 155.56%. Given Immunovant's higher probable upside, analysts plainly believe Immunovant is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immunovant	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90

Does the MarketBeat Community believe in ABUS or IMVT?

Arbutus Biopharma received 304 more outperform votes than Immunovant when rated by MarketBeat users. However, 77.65% of users gave Immunovant an outperform vote while only 70.66% of users gave Arbutus Biopharma an outperform vote.

Company	Underperform	Outperform
Arbutus Biopharma	Outperform Votes 436 70.66%	Underperform Votes 181 29.34%
Immunovant	Outperform Votes 132 77.65%	Underperform Votes 38 22.35%

Is ABUS or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,137.65%. Arbutus Biopharma's return on equity of -68.18% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	-1,137.65%	-68.18%	-51.55%
Immunovant	N/A	-77.94%	-69.82%

Which has stronger valuation & earnings, ABUS or IMVT?

Arbutus Biopharma has higher revenue and earnings than Immunovant. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$6.17M	99.63	-$72.85M	-$0.41	-7.83
Immunovant	N/A	N/A	-$259.34M	-$2.62	-5.73

Do insiders & institutionals have more ownership in ABUS or IMVT?

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 20.3% of Arbutus Biopharma shares are held by company insiders. Comparatively, 5.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Arbutus Biopharma and Immunovant tied by winning 9 of the 18 factors compared between the two stocks.